Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.

ABSTRACT:

Background

A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation.

Methods

In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group.

SUBMITTER: Kooistra EJ 

PROVIDER: S-EPMC7726611 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature